The FDA has approved Exact Sciences Corp.’s Cologuard Plus test, a next-generation stool DNA test for colorectal cancer (CRC) screening in adults aged 45 and older. This approval is based on the BLUE-C study, demonstrating superior performance compared to its predecessor, Cologuard, and other fecal immunochemical tests. Cologuard Plus will be available in 2025, supported by ExactNexus technology and anticipated Medicare coverage.
Gritstone Bio’s GRANITE, an individualized neoantigen-targeting immunotherapy, demonstrated potential in treating microsatellite-stable colorectal cancer (MSS-CRC). While the interim Phase 2 data showed positive results, particularly in patients with lower disease burden, the stock price declined due to concerns about the overall impact and future development plans. The company will discuss the progression-free survival data with the FDA and explore potential Phase 2 or 3 trials using ctDNA levels as eligibility criteria.
Merck & Co’s experimental fixed-dose combination of favezelimab and pembrolizumab failed to improve overall survival in patients with pretreated microsatellite-stable metastatic colorectal cancer (mCRC) in a Phase 3 study. The study, KEYFORM-007, did not meet its primary endpoint, leading to a setback for the company. Despite this, Merck’s Keytruda continues to secure approvals for other cancer types.
Scientists have discovered specific molecules in the blood that could potentially predict the risk of colorectal cancer in young adults. These findings could lead to early screening and preventive measures for this increasingly common cancer in younger generations.
Turnstone Biologics Corp. (TSBX) saw its stock decline after releasing initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC). The data showed positive results, including a 25% overall response rate and a 50% disease control rate, with one patient experiencing a complete response. Despite the encouraging results, the company is now focusing on colorectal, head and neck, and uveal melanoma indications, deprioritizing cutaneous melanoma and breast cancer.
Cancer is a serious disease, but it is important to remember that it is not always a death sentence. Advances in medicine have made it possible to treat many types of cancer, and even those that cannot be cured can often be managed to prolong life. It is important to be aware of the risks of cancer and to take steps to reduce your risk, but it is also important to avoid becoming overly fearful of the disease. If you are diagnosed with cancer, it is important to seek treatment as soon as possible. Early detection and treatment can improve your chances of survival.
While a recent study introduces a blood test for early colorectal cancer detection, experts emphasize that colonoscopies remain crucial for prevention and early detection. The shift from prevention to detection could increase cancer diagnoses and mortality. Blood tests should complement, not replace, colonoscopies as the gold standard of care.
With colon cancer cases rising, researchers are developing new blood tests to enhance detection. The tests search for altered DNA associated with the disease and are expected to complement existing screening methods like colonoscopies and stool tests. Targeted initially for individuals with a high family history of colon cancer, these tests aim to make screening more accessible and effective. Meanwhile, colonoscopies remain the preferred method for detecting colon cancer, with screening recommended at age 45 or earlier for those with a family history.
Colorectal cancer is a significant threat, and early detection and treatment of precancerous lesions, such as large polyps, are essential. Endoscopy offers minimally invasive options for removing these polyps, including Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Both techniques aim to remove polyps completely, preventing their progression to CRC. EMR is commonly employed for simpler polyps, while ESD is preferred for complex polyps with a higher risk of invasion. While ESD offers higher en-bloc resection rates, it is a more complex procedure and requires greater expertise. The choice between EMR and ESD should be customized based on patient-specific factors and available expertise.
Colorectal cancer, a prevalent global health concern, stems from abnormal cell growth in the colon and rectum. Often developing from polyps that evolve into malignant tumors, this cancer ranks third among the most common cancers worldwide. Age, genetic predisposition, an unhealthy diet, and sedentary lifestyles serve as prominent triggers. Symptoms usually manifest in advanced stages, including altered bowel habits, bloody stools, and abdominal discomfort. Treatment options depend on the cancer’s stage and may encompass surgery, chemotherapy, and radiation. Early detection through screenings is vital for effective management and reducing mortality rates. A healthy lifestyle, including ample fruit, vegetable, and whole grain intake, coupled with reduced alcohol and tobacco use, is instrumental in prevention. Regular screenings, such as colonoscopies, aid in detecting polyps before they become cancerous. Ongoing research focuses on personalized medicine and targeted therapies based on individual genetic profiles. Advances in gene mutation identification, immunotherapy, and drug development show promise but necessitate further investigation and testing.
